source
- FDA cuts required analytical tests for emergency-use diagnostic devices in new guidanceOn 9 November 2026 the U.S. Food and Drug Administration released final guidance aimed at simplifying validation of in-vitro diagnostic devices used in public-health emergencies. The document outli…
- Phase 3 trial shows Zealand-Boehringer obesity drug survodutide does not raise cardiovascular death riskThe Phase 3 SYNCHRONIZE-CVOT study found that survodutide, the joint obesity therapy from Zealand and Boehringer Ingelheim, was non‑inferior to placebo for cardiovascular death, indicating no added…